This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
6 Reasons Why You Should Hold on to Cboe Global Stock Now
by Zacks Equity Research
Cboe Global Markets (CBOE) remains well-poised for growth on the back of its strong market position and a global reach with potent proprietary products.
UnitedHealth Extends LabCorp Ties, Signs Quest Diagnostic Deal
by Zacks Equity Research
UnitedHealth (UNH) agrees with laboratories and diagnostic companies for value based care.
Anthem to Buy Aspire Health for Better Healthcare Service
by Zacks Equity Research
Anthem (ANTM) agrees to take over Aspire Health for providing better and integrated medical care outside hospital.
Zacks Industry Outlook Highlights: UnitedHealth, Anthem, Aetna, Cigna and Humana
by Zacks Equity Research
Zacks Industry Outlook Highlights: UnitedHealth, Anthem, Aetna, Cigna and Humana
Cigna Q1 Earnings Top on Higher Enrollment, 2018 View Up
by Zacks Equity Research
Cigna (CI) Q1 earnings gain from an increase in membership and revenue growth.
Cigna (CI) Beats on Q1 Earnings & Revenues, Guides Up
by Zacks Equity Research
Cigna (CI) Q1 earnings gain from higher revenue and enrollment.
Why Earnings Season Could Be Great for Cigna (CI)
by Zacks Equity Research
Cigna (CI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
What's in Store for Intercontinental Exchange (ICE) in Q1?
by Zacks Equity Research
Robust revenues across data service, trading and clearing plus listing segments are expected to drive Intercontinental Exchange's (ICE) Q1. However, rising expenses might be a spoiler.
Will Cigna (CI) Beat Q1 Earnings Estimates This Time Again?
by Zacks Equity Research
Cigna (CI) Q1 earnings to see upside from higher revenues, enrollment growth.
Can U.S. Mortgage Insurance Aid Genworth (GNW) Q1 Earnings?
by Zacks Equity Research
Impressive performance at U.S. Mortgage Insurance, approval of rate hike over time and a solid insurance in force improving premiums should aid Genworth's (GNW) first-quarter results.
What's in the Cards for Assurant (AIZ) This Earnings Season?
by Zacks Equity Research
Stronger performance at most business lines is likely to aid Assurant's (AIZ) Q1 earnings.
What's in Store for Prudential Financial (PRU) Q1 Earnings?
by Zacks Equity Research
Better-than-expected results at U.S. Individual Solutions and Investment Management segment along with higher investment income and AUM growth might drive Prudential Financial (PRU) in Q1.
Will Higher Premiums Drive XL Group's (XL) Q1 Earnings?
by Zacks Equity Research
Better investment results and premium growth are likely to aid XL Group's (XL) Q1 earnings. However, escalating expenses and a massive cat loss might be dampeners.
Arthur J. Gallagher (AJG) Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher revenues and better-than-expected organic growth might drive Arthur J. Gallagher's (AJG) Q1 earnings performance. However, rising expenses might be a spoiler.
What's in Store for Unum Group (UNM) This Earnings Season?
by Zacks Equity Research
Better performances at Unum U.S. and Colonial Life are likely to aid Unum Group's (UNM) first-quarter earnings.
Will Higher Premiums Aid CNA Financial's (CNA) Q1 Earnings?
by Zacks Equity Research
Improved premiums and better investment results might drive CNA Financial (CNA) in Q1. However, rising expenses and a probable catastrophe loss might act as dampeners.
Humana (HUM) Shores Up Government Business With FPG Buyout
by Zacks Equity Research
Humana's (HUM) Medicare business is expected to benefit from its strategic acquisitions.
Check These 3 Health Insurers to Reap High Returns in Q2
by Zacks Equity Research
We streamline our search to three best insurance bets with potential to turn investors rich by garnering fat returns.
Centene Makes Investment in RxAdvance, Builds Partnership
by Zacks Equity Research
Centene's (CNC) transformative alliance with RxAdvance is another instance of Health insurers joining forces with pharmacy benefit managers to reduce the costs in the drug supply chain.
Cigna on Raters' Radar After Express Scripts Bid, Stock Down
by Zacks Equity Research
Cigna (CI) gets rating downgrade on a number of concerns related to the Express Scripts deal.
Buy These 3 Stocks as Healthcare Continues to Shift Gears
by Zacks Equity Research
Mergers and acquisition in the healthcare industry should aid long term-growth for companies.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Cigna, Express Script Deal to Continue Healthcare Reshuffle
by Zacks Equity Research
Cigna's (CI) acquisition of Express Scripts should transform it into a more diversified entity.
Hartford Financial to Buy Foremost Small Commercial Lines
by Zacks Equity Research
Hartford Financial's (HIG) acquisitions aim to improve its segmental performances.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal